New technologies and techniques for prostate cancer focal therapy.

Détails

ID Serval
serval:BIB_84639820903A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
New technologies and techniques for prostate cancer focal therapy.
Périodique
Minerva urologica e nefrologica = The Italian journal of urology and nephrology
Auteur(s)
Linares-Espinós E., Carneiro A., Martínez-Salamanca J.I., Bianco F., Castro-Alfaro A., Cathelineau X., Valerio M., Sanchez-Salas R.
ISSN
1827-1758 (Electronic)
ISSN-L
0393-2249
Statut éditorial
Publié
Date de publication
06/2018
Peer-reviewed
Oui
Volume
70
Numéro
3
Pages
252-263
Langue
anglais
Notes
Publication types: Journal Article ; Meta-Analysis ; Review
Publication Status: ppublish
Résumé
The aim of this study was to review the oncological and functional outcomes of new and established primary focal treatments (FT) for localized prostate cancer (PCa).
We performed a systematic search of published studies on FT for localized PCa using electronic databases (Medline and Embase). These studies included reports on hemi-ablation, focal ablation and target-ablation. We excluded salvage focal therapy studies and limited the search to those with a minimum of 12 months of follow-up.
We selected 20 studies with a total of 2523 patients who were treated in the primary setting. The energy sources used were cryotherapy (8), high-intensity focused ultrasound (9), irreversible electroporation (1), photodynamic therapy (1) and focused laser ablation (1), with 65% hemiablation, 25% focal ablation and 10% target-ablation. The median follow-ups ranged from 6 to 44.4 months. Mean age was 60.4-70 years and mean prostate-specific antigen was 4.4-<10 ng/dL; 26-100% had a Gleason Score of 6, and 0-65% had a Gleason Score of 7. Patient selection was carried out by TRUS biopsy in 9 studies, while transperineal template mapping biopsy and mp-MRI were employed in six and 13 studies, respectively. The overall post-treatment positive biopsy rate was 1.2-51% with 1.6-32% patients having a residual disease in the treated area. The post-treatment continence rates were 90-100%, and the rates of erectile dysfunction ranged from 0-53.2%.
Reliable evidence for the partial-gland treatment of PCa is increasing, and encouraging mid-term oncologic outcomes with the preservation of sexual and urinary functions have been reported. Accurate patient selection at the outset of treatment and careful follow-up seem key attributes to achieve excellent functional results and encouraging oncological outcomes.
Mots-clé
Ablation Techniques, Cryotherapy, Electroporation, Evidence-Based Medicine, Humans, Male, Phototherapy, Prostatic Neoplasms/diagnostic imaging, Prostatic Neoplasms/drug therapy, Prostatic Neoplasms/therapy
Pubmed
Web of science
Création de la notice
19/04/2018 18:21
Dernière modification de la notice
07/12/2018 7:26
Données d'usage